Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T-cells

CRISPR–Cas9 mediated genome editing offers unprecedented opportunities for treating human diseases. There are several reports that demonstrate pre-existing immune responses to Cas9 which may have implications for clinical development of CRISPR-Cas9 mediated gene therapy. Here we use 209 overlapping...

Descripción completa

Detalles Bibliográficos
Autores principales: Simhadri, Vijaya L., Hopkins, Louis, McGill, Joseph R., Duke, Brian R., Mukherjee, Swati, Zhang, Kate, Sauna, Zuben E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384835/
https://www.ncbi.nlm.nih.gov/pubmed/34429421
http://dx.doi.org/10.1038/s41467-021-25414-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384835/
https://www.ncbi.nlm.nih.gov/pubmed/34429421
http://dx.doi.org/10.1038/s41467-021-25414-9

Ejemplares similares